ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has entered into a licensing partnership with Korea Research Institute of Chemical Technology (“KRICT”) regarding the development of a synthetic process for Quinoxalines compounds. Research has demonstrated that Quinoxalines provide selective toxicity towards hypoxic cells - cells found in solid tumors and that are resistant to anticancer drugs and radiation therapy. This makes Quinoxaline-based drugs a potential potent treatment for solid tumors.
